Ixazomib | List of Frontiers open access articles

Original Research

Published on 05 Jan 2026

Pharmacovigilance study on neurological adverse reactions of proteasome inhibitors in the FDA adverse event reporting system

in Pharmacoepidemiology

Shuyue Li
Tao Ling
Yan Liu
Jun Li

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1712361

1,143 views

Original Research

Published on 15 May 2025

Efficacy of MLN9708 (ixazomib) in experimental autoimmune myasthenia gravis and in anti-AChR producing primary thymic cell cultures from myasthenia gravis patients

in Autoimmune and Autoinflammatory Disorders : Autoimmune Disorders

Marina Mané-Damas
Abhishek Saxena
Gisela Nogales-Gadea
Jo Stevens
Shannen Vincken
Maarten van Beek
Nynke J. van den Hoogen
Elbert A. J. Joosten
Nick Willcox
Hans Duimel

Frontiers in Immunology

doi 10.3389/fimmu.2025.1521432

3,494 views
2 citations

Review

Published on 10 Nov 2021

Carfilzomib: A Promising Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma

in Cancer Molecular Targets and Therapeutics

Shansa Pranami E. Jayaweera
Sacheela Prasadi Wanigasinghe Kanakanamge
Dharshika Rajalingam
Gayathri N. Silva

Frontiers in Oncology

doi 10.3389/fonc.2021.740796

25,227 views
83 citations

Original Research

Published on 03 Sep 2024

Signal mining of adverse events of proteasome inhibitors in multiple myeloma based on FAERS

in Drugs Outcomes Research and Policies

Yuan Peng
Yuying Zhou
Kaisen Shu
Xu Jia
Yan Zhong

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1396378

2,560 views
4 citations

Original Research

Published on 09 May 2022

Molecular Taxonomy of Systemic Lupus Erythematosus Through Data-Driven Patient Stratification: Molecular Endotypes and Cluster-Tailored Drugs

in Autoimmune and Autoinflammatory Disorders

Panagiotis Garantziotis
Dimitrios Nikolakis
Stavros Doumas
Eleni Frangou
George Sentis
Anastasia Filia
Antonis Fanouriakis
George Bertsias
Dimitrios T. Boumpas

Frontiers in Immunology

doi 10.3389/fimmu.2022.860726

8,460 views
25 citations

Original Research

Published on 29 Jan 2026

Efficacy and safety of Ixazomib-based maintenance therapy after autologous hematopoietic stem cell transplantation in multiple myeloma patients: a retrospective analysis

in Hematology

Mengyuan Chen
Gang Chen
Jianli Xu
Kaile Zhang
Ruixue Yang
Chunxia Han
Jia Hou
Ming Jiang
Hailong Yuan

Frontiers in Medicine

doi 10.3389/fmed.2026.1680704

903 views

Systematic Review

Published on 13 May 2025

The efficacy of new drug regimens in treating newly diagnosed high-risk cytogenetic multiple myeloma patients: a systematic literature review and meta-analysis

in Hematology

Huixing Zhou
Wenming Chen

Frontiers in Medicine

doi 10.3389/fmed.2025.1575914

4,396 views

Original Research

Published on 22 May 2023

Continuous low-dose cyclophosphamide plus prednisone in the treatment of relapsed and refractory multiple myeloma with severe complications

in Cancer Molecular Targets and Therapeutics

Haotian Shi
Wei Wei
Rong Peng
Haimin Chen
Nian Zhou
Lixia Wu
Wenjun Yu
Wenhao Zhao
Jian Hou
Fan Zhou

Frontiers in Oncology

doi 10.3389/fonc.2023.1185991

3,821 views
2 citations

Articles

Pharmacovigilance study on neurological adverse reactions of proteasome inhibitors in the FDA adverse event reporting system

Efficacy of MLN9708 (ixazomib) in experimental autoimmune myasthenia gravis and in anti-AChR producing primary thymic cell cultures from myasthenia gravis patients

Carfilzomib: A Promising Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma

Signal mining of adverse events of proteasome inhibitors in multiple myeloma based on FAERS

Molecular Taxonomy of Systemic Lupus Erythematosus Through Data-Driven Patient Stratification: Molecular Endotypes and Cluster-Tailored Drugs

Efficacy and safety of Ixazomib-based maintenance therapy after autologous hematopoietic stem cell transplantation in multiple myeloma patients: a retrospective analysis

The efficacy of new drug regimens in treating newly diagnosed high-risk cytogenetic multiple myeloma patients: a systematic literature review and meta-analysis

Continuous low-dose cyclophosphamide plus prednisone in the treatment of relapsed and refractory multiple myeloma with severe complications